N/A N=106 Accuracy of Blood Loss Estimation After Vaginal Delivery
Postpartum Hemorrhage
Primary: Difference in Actual Blood Volume and Estimated Blood Volume in Milliliters. — -20.8; -41.7; -53.5; -96.0 milliliters — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Coagulation Factor Changes Associated With Postpartum Hysterectomies
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
N/A N=99,659 A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth
Post-Partum Haemorrhage
Primary: The Primary Outcome is a Composite of the Following Three Clinical Outcomes: 1) Severe PPH Defined as Blood Loss ≥1000 ml or; 2) Postpartum Laparotomy for Bleeding or…
Phase 2 N=43 Prevention of Postpartum Hemorrhage With Tranexamic Acid
Postpartum Hemorrhage
Primary: PK Model Parameter Estimates — 8.85; 10.39; 9.45 L/hr
N/A N=10 Feasibility Clinical Investigation Using the InPress Device for the Treatment of Postpartum Hemorrhage
Post Partum Hemorrhage
Primary: Number of Related SAE — 0 SAEs
Phase 3 N=120 Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
Uterine Atony · Uterine Atony With Hemorrhage · Postpartum Hemorrhage
Primary: Quantitative Blood Loss — 840; 1051 milliliters — p=<0.05
Phase 4 N=437 Fibrinogen in Haemorrhage of Delivery
Post-Partum Hemorrhage
Primary: Failure Rate of PPH Management — 75; 80; 92; 92 Participants — p=0.9563
N/A N=242 Validating a New Method to Assess Estimated Blood Loss in the Obstetric Population
Pregnancy Complications
Primary: Clinical Estimated Blood Loss (EBL) Between Cases and Controls Using Clinical Estimate Versus Device Assessment — 800; 800 milliLiters
Phase 4 N=160 Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients
Uterine Atony With Hemorrhage
Primary: Number of Participants With Need for Additional Uterotonics (Methylergonovine, Carboprost, Misoprostol) — 80; 80 Participants
Phase 4 N=100 Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial
Postpartum Hemorrhage · Uterine Atony
Primary: Uterine Tone Score — 4.7; 4.4 score on a scale
N/A N=107 Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
Postpartum Hemorrhage
Primary: Efficacy: Rate of Participants With Cessation of Uterine Hemorrhaging — 100 Participants
N/A N=343 Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy
Hypertension, Pregnancy-Induced · Postpartum Preeclampsia · Hypertension; Maternal
Primary: Proportion of Participants With Recorded Blood Pressure Values in Office — 43; 44; 49; 56 Participants
Phase 4 N=123 Buccal Misoprostol During Cesarean Section for Preventing Postpartum Hemorrhage
Postpartum Hemorrhage
Primary: Need for Additional Uterotonic Medications — 10; 40 percentage of participants — p=<0.01
N/A N=4 Temporary Aortic Occlusion With the Abdominal Tourniquet for Refractory Postpartum Haemorrhage: A Proof-of-Concept Study in a War-Affected Region
Postpartum Haemorrhage (PPH)
Primary: Time to Bleeding Control After AAJT-S Device Application — 2 Minutes
Phase 4 N=1,798 Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT
Uterine Atony · Postpartum Hemorrhage
Primary: Number of Subjects Reporting Uterine Atony or Postpartum Hemorrhage Requiring Medical (Medication or Blood Transfusion), Surgical or Other Interventional Treatment — 45…
Phase 2 N=100 The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
Hemorrhage
Primary: The Amount of Hemorrhage During Cesarean Delivery and Within 2 Hours Afterward — 260; 380 ml
Phase 3 N=11,000 Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean
Obstetrical Complications · Hemorrhage · Labor and Delivery
Primary: Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells — 201; 233 Participants — p=0.19
Phase 3 N=506 Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section
Post Partum Hemorrhage
Primary: Number of Participants With Postpartum Haemorrhage (PPH) — 48; 54; 56; 71 Participants — p=0.549
Phase 3 N=1,226 The Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Caesarean Section
Postpartum Hemorrhage
Primary: Number of Participants With Postpartum Hemorrhage (PPH) — 409; 399; 111; 125 Participants — p=0.33
N/A N=200 Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage
Postpartum Hemorrhage · Uterine Atony
Primary: Blood Loss — 616; 418; 141; 106 cc
Phase 2 N=118 ToRsemide for pOstpartum HYpertension
Preeclampsia
Primary: Number of Participants With Persistent Postpartum Hypertension Defined as Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHg — 26; 34 Participants
N/A N=10 Feasibility Trial of the Circumferential Abdominal Pelvic Pressure Device (CAPP)
Postpartum Hemorrhage
Primary: Usage — 10 participants
Phase 3 N=20 Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Von Willebrand Diseases · Postpartum Hemorrhage
Primary: Volume of Quantitative Blood Loss at Delivery — 727.0; 539.7 mL
N/A N=66 SMaRT Blood: Single-unit Versus Multiple-unit Packed Red Blood Cell Transfusion in Non-acute Postpartum Anemia
Postpartum Anemia Nos
Primary: Total Number of Units Transfused — 1.2; 2.1 units of blood — p=<0.001
Phase 3 N=62 PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot
Venous Thromboembolism · Postpartum
Primary: Feasibility of Recruitment and Trial Operations. — 0.9; 0.9 participants per site per month
N/A N=213 Remote BP Monitoring in the PP Period
Hypertensive Disorder of Pregnancy
Primary: Blood Pressure (BP) Surveillance Adherence — 0.0; 61.1 percentage of recommended BPs reported
N/A N=206 Remote Surveillance of Postpartum Hypertension
Hypertension in Pregnancy
Primary: Number of Participants Whose Blood Pressure Was Assessed in the First Ten Days Following Discharge — 45; 95 Participants
Phase 4 N=61 Optimal Blood Pressure Treatment Thresholds Postpartum
Hypertensive Disorder of Pregnancy · Pre-Eclampsia · Hypertension
Primary: Percent of Participants Eligible, Enrolled and Retained (Feasibility) — 61 Participants
Phase 3 N=82 Lasix for the Prevention of De Novo Postpartum Hypertension
Postpartum Pregnancy-Induced Hypertension · Postpartum Preeclampsia · Hypertension, Pregnancy-Induced
Primary: Mean Arterial Blood Pressure (MAP) — 88.9; 86.8 mmHg
Phase 2 N=384 Furosemide for Accelerated Recovery of Blood Pressure Postpartum
Hypertension, Pregnancy-Induced
Primary: Persistently Elevated Blood Pressures 7 Days Postpartum — 10; 23 Participants — p=0.03